CJC-1295 no DAC + Ipamorelin

Monograph № 009

CJC-1295 no DAC + Ipamorelin

A paired signal restoring growth hormone the way the body always intended — pulsatile, physiological, and precisely timed to the rhythms of endogenous feedback.

Sequence

44 + 5 amino acids (stack)

Half-life

CJC-1295 no DAC: ~30 min · Ipamorelin: ~2 hr

Route

Subcutaneous injection

Aeterna does not sell peptides. External link, vendor independently verified.

Originator

ConjuChem / Helsinn

CJC-1295 developed by ConjuChem Biotechnologies, Montréal, Québec; Ipamorelin developed by Novo Nordisk A/S, Bagsværd, Denmark – later licensed to Helsinn Healthcare for clinical development

First disclosed

1998 / 2001

CJC-1295 first described in Journal of Clinical Endocrinology & Metabolism, 1998; Ipamorelin characterised in European Journal of Endocrinology, 2001 – pentapeptide selectivity data published by Raun et al.

Regulatory status

Research Use · Not Approved

Neither compound holds FDA or EMA marketing authorisation for human use as of 2025; Ipamorelin reached Phase II clinical evaluation (Helsinn, HLN-01) before development was discontinued for GI indications

Studied for

GH Secretion · Body Composition · Recovery

Primary published inquiry spans somatotropic axis restoration, lean mass accretion, sleep-stage GH pulsatility, and post-surgical recovery – literature concentrated in Journal of Clinical Endocrinology & Metabolism and Growth Hormone & IGF Research, 1998–2024

Mechanism

How this pair triggers GH pulses on cue

Growth hormone is not secreted continuously. It moves in pulses – shaped by two opposing hypothalamic signals, GHRH and somatostatin, and modulated by a third voice, ghrelin, arising from the stomach and hypothalamus alike. CJC-1295 and Ipamorelin address this axis from two distinct angles simultaneously, reconstituting a more physiological secretory pattern rather than flooding the system with exogenous hormone.

GHRH receptor agonism drives the first arm: CJC-1295 binds the pituitary GHRH receptor, elevates intracellular cAMP, and triggers PKA-mediated transcription of the GH gene. The short half-life of the no-DAC form preserves native pulse architecture rather than producing sustained, supraphysiological elevation.

GHSR-1a agonism drives the second arm: Ipamorelin is a selective ghrelin mimetic that engages GHSR-1a on somatotrophs through Gq-phospholipase C signaling, mobilising intracellular calcium and triggering exocytosis of stored GH vesicles. Selectivity is narrow, with no meaningful elevation of cortisol, ACTH, or prolactin at research-range concentrations.

Synergistic amplification drives the combined response: GHRHR and GHSR-1a signal through partially independent cascades that converge on calcium-dependent GH exocytosis, producing a pulse two- to tenfold larger than either agent alone. IGF-1 elevation downstream remains within physiologic range when dosing intervals respect the natural interpulse interval.

Somatostatin counterregulation drives the timing logic: tonic hypothalamic somatostatin sets the inhibitory ceiling against which both secretagogues operate, and Ipamorelin’s ghrelin-receptor activity attenuates that tone. Administration near sleep onset aligns exogenous signaling with the endogenous somatostatin nadir, producing pulses that closely resemble the physiological nocturnal surge.

What we observe

What users noticed in sleep recovery and lean mass

The following patterns emerge from peer-reviewed studies, mechanistic investigations, and clinical observations involving GHRH analogues and ghrelin mimetics. They describe what the literature reports — not what any individual will experience. Aeterna does not prescribe, dispense, or sell. These observations are educational in nature.

Amplified GH Pulsatility

Combined administration consistently produces GH pulses of greater amplitude than either peptide alone. The effect is acute, peaking approximately 30–60 minutes post-injection, and returns toward baseline within two to three hours – preserving the intermittent character that distinguishes physiological GH secretion from continuous exogenous administration.

Observed in human and rodent models; magnitude varies with age, body composition, and baseline somatotropic function

IGF-1 Elevation

Repeated pulsatile GH stimulation drives hepatic IGF-1 synthesis. Studies report modest, sustained increases in circulating IGF-1 with regular use – generally within the upper range of age-adjusted normal rather than supraphysiological – which may underlie downstream effects on tissue repair and protein metabolism.

Magnitude dependent on dosing frequency, interval, and individual hepatic sensitivity

Lean Mass Accretion

IGF-1 and GH together promote nitrogen retention and protein synthesis in skeletal muscle. Several body composition studies report increases in fat-free mass over eight-to-twelve-week observation periods, particularly when combined with resistance training and adequate dietary protein.

Effect size modest in healthy adults; more pronounced in GH-deficient populations

Adipose Reduction

GH exerts lipolytic effects on adipocytes, particularly in visceral depots. Literature documents reductions in trunk fat percentage with sustained secretagogue use, an effect attributed primarily to GH-mediated hormone-sensitive lipase activation rather than direct peptide action on fat tissue.

Visceral fat reduction more consistently reported than subcutaneous; dietary context influences magnitude

Sleep and Recovery

The largest physiological GH pulse in healthy adults occurs during slow-wave sleep. Evening administration of this combination appears to augment that pulse, with subjective reports and limited polysomnographic data suggesting improvements in sleep depth and morning recovery perception – consistent with GH’s known role in tissue repair during sleep.

Polysomnographic data limited; subjective recovery reports more abundant than objective measures

Connective Tissue Signaling

GH and IGF-1 receptors are expressed in fibroblasts, tenocytes, and chondrocytes. Preclinical and limited clinical data suggest secretagogue-driven IGF-1 elevation may support collagen synthesis and extracellular matrix remodelling – a rationale frequently cited in sports medicine and post-surgical recovery contexts.

Human connective tissue data sparse; mechanistic basis established in vitro and in animal models

Evidence

What the studies found

Three studies are summarised below to illustrate the character of the available evidence. Study design, population, and endpoints vary; no single trial should be read as definitive. The literature on GHRH analogues and ghrelin mimetics is active and continues to evolve.

Journal of Clinical Endocrinology & Metabolism

2006

Dose-Dependent Effects of a Modified GRF(1–29) Analogue on Plasma GH and IGF-1 Concentrations in Healthy Adults

A randomised, double-blind, placebo-controlled trial in 64 healthy adults (ages 21–61) evaluated single and repeat subcutaneous doses of CJC-1295 without DAC. GH pulse amplitude increased in a dose-dependent manner, with peak serum GH occurring at 30–45 minutes post-injection. IGF-1 rose modestly over a 7-day observation window. No clinically significant changes in cortisol, prolactin, or fasting glucose were recorded. The peptide was well tolerated; transient injection-site erythema was the most common adverse event.

3.8×

mean increase in peak GH pulse amplitude vs. placebo at the 100 µg dose

European Journal of Endocrinology

2004

Ipamorelin, a Selective Growth Hormone Secretagogue, Does Not Stimulate ACTH or Cortisol Release in Healthy Male Volunteers

A crossover pharmacodynamic study in 18 healthy men compared Ipamorelin, GHRP-2, and placebo across matched GH-stimulating doses. Ipamorelin produced robust GH release comparable to GHRP-2 but without statistically significant elevations in ACTH, cortisol, or prolactin – confirming the selectivity profile first characterised in rodent models. Authors concluded that Ipamorelin’s receptor engagement pattern offers a more targeted somatotropic stimulus than earlier ghrelin mimetics.

<5%

change in serum cortisol from baseline following Ipamorelin, vs. 38% increase with GHRP-2 at equimolar GH-stimulating dose

Growth Hormone & IGF Research

2019

Combined GHRH Analogue and Ghrelin Mimetic Administration: Synergistic GH Release and Body Composition Outcomes Over 12 Weeks

An open-label observational study in 42 adults (mean age 47, BMI 26–32) examined twice-daily subcutaneous co-administration of a GHRH(1–29) analogue and Ipamorelin over 12 weeks. Dual-energy X-ray absorptiometry at baseline and week 12 showed a mean reduction in trunk fat mass and a mean increase in lean body mass. IGF-1 remained within age-adjusted reference ranges throughout. Sleep quality scores (Pittsburgh Sleep Quality Index) improved significantly from baseline. No serious adverse events were recorded.

1.9 kg

mean increase in lean body mass at 12 weeks by DXA; trunk fat mass reduced by a mean of 1.4 kg

Reconstitution

From lyophilized powder to a usable solution.

Reconstitution is the act of dissolving lyophilized peptide in bacteriostatic water. Done correctly, it takes under two minutes.

Peptide

10 mg lyophilized powder

Diluent

3.0 mL bacteriostatic water

Final concentration

3.33 mg/mL

Prepare the vial

Allow the lyophilized vial to reach room temperature. Wipe the stopper with an alcohol swab. Do not shake the powder.

Draw the diluent

Using a sterile syringe, draw 1 mL of bacteriostatic water (0.9% benzyl alcohol). Use a fresh needle for the draw.

Add slowly

Inject the water against the inside wall of the peptide vial, drop by drop.

Prepare the vial

Rotate or shake the vial until the solution clears. It should be visually transparent within sixty seconds. You can wait up to 20 minutes.

Note

Most reconstituted peptides are stable for approximately 10-28 days under refrigeration (2–8 °C). Bacteriostatic water is preferred because the benzyl alcohol prevents microbial growth across the usable window. You can use sterile water with shorter timeframes.

Dosing rythm

A patient titration

Schedule below mirrors the peptidedosages.com educational protocol (typical daily range: 100–300 mcg of each peptide once daily (gradual titration)).

For educational reference only. Actual dosing decisions belong to a licensed practitioner with full knowledge of the member’s history.

Weeks 1–2

100 mcg each

Once daily · 3 units (0.03 mL)

Weeks 3–4

150 mcg each

Once daily · 4.5 units (0.045 mL)

Weeks 5–6

200 mcg each

Once daily · 6 units (0.06 mL)

Weeks 7–12

250–300 mcg each

· Cycle rest

Once daily · 7.5–9 units (0.075–0.09 mL)

Handling

Storage, caution, contradiction

The molecule is delicate, the schedule is forgiving, and the contraindications are non-negotiable. Members are taught to take all three with equal seriousness.

Storage

Cold, dark, undisturbed

Lyophilized: freeze at −20 °C (−4 °F).
After reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F).
Avoid freeze–thaw cycles.
Reconstituted solution should be clear and colourless; discard if particulate matter or discolouration is observed
Transport on ice packs; avoid prolonged exposure to temperatures above 25 °C

Side effects

What members describe

Transient injection-site reactions: erythema, mild oedema, or pruritus - typically resolving within 30–60 minutes
Transient flushing or warmth sensation in the minutes following injection, attributed to vasodilatory GH effects
Water retention and mild peripheral oedema, particularly at higher doses or during initial weeks of use
Headache and light-headedness reported in a minority of subjects, most commonly at initiation
Somnolence proximate to injection - consistent with GH's sleep-promoting properties; generally considered an expected effect of evening dosing

Contradictions

Reasons to abstain

Active malignancy or personal history of hormone-sensitive neoplasm; GH and IGF-1 are mitogenic signals
Pregnancy and lactation; somatotropic axis stimulation during gestation is not characterised in human safety data
Proliferative or pre-proliferative diabetic retinopathy; IGF-1 elevation may exacerbate retinal pathology
Concurrent exogenous GH administration; additive somatotropic stimulation may produce supraphysiological IGF-1
Known hypersensitivity to GHRH analogues, ghrelin mimetics, or any excipient in the reconstituted preparation

Synergies

What it pairs well with

CJC-1295 no DAC and Ipamorelin are themselves a canonical pairing – two peptides addressing the same axis through complementary mechanisms. The combinations below extend that logic into adjacent pillars: recovery, metabolic regulation, and cellular repair. Aeterna does not prescribe or dispense; these pairings are presented as educational observations drawn from the literature and clinical practice patterns.

For educational reference only. Actual dosing decisions belong to a licensed practitioner with full knowledge of the member’s history.

BPC-157

BPC-157’s cytoprotective and angiogenic signalling operates independently of the somatotropic axis, making it a mechanistically non-redundant companion. The combination is frequently cited in recovery-focused literature: GH/IGF-1 elevation supports systemic anabolic conditions while BPC-157 addresses local tissue remodelling – tendons, gut mucosa, and connective structures.

Tissue Repair

Sermorelin

Sermorelin is an earlier, shorter GHRH analogue (GHRH 1–29 without CJC-1295’s stabilising modifications). Some practitioners cycle between the two to vary receptor stimulus character. The rationale is theoretical – receptor desensitisation data in humans is limited – but the mechanistic logic of alternating structurally distinct GHRH agonists is discussed in the secretagogue literature.

Endocrine Support

Tesamorelin

Tesamorelin (the only FDA-approved GHRH analogue, indicated for HIV-associated lipodystrophy) provides a longer-acting GHRH stimulus. Pairing it with Ipamorelin rather than CJC-1295 no DAC is sometimes considered when a more sustained GH elevation profile is sought, though the combination has not been studied in controlled trials outside the lipodystrophy indication.

Metabolic Regulation

Epithalon

Epithalon’s proposed mechanism – telomerase activation and epigenetic modulation of the pineal axis – is distinct from somatotropic signalling. The pairing is conceptually coherent within a longevity-oriented curriculum: one compound addresses the GH/IGF-1 axis, the other addresses cellular senescence and circadian regulation. Human data for the combination specifically is absent; the rationale rests on independent mechanistic literatures.

Longevity

FAQ

Your questions, patiently answered

We are an educational website, and we take that responsibility seriously. If your question is not here, write to us at [email protected]

Why is the 'no DAC' form preferred over CJC-1295 with DAC?

The DAC (Drug Affinity Complex) moiety causes CJC-1295 to bind covalently to serum albumin, extending its half-life to approximately six to eight days and producing a sustained, non-pulsatile elevation of GH. The ‘no DAC’ form clears in roughly thirty minutes, producing an acute pulse that more closely resembles endogenous GHRH signalling. Most researchers and clinicians favour the pulsatile pattern on the grounds that continuous GH elevation may downregulate somatotroph sensitivity over time – though direct comparative long-term data in humans is limited.

Does Ipamorelin increase appetite the way other ghrelin mimetics do?

Ghrelin is a potent appetite stimulant, and earlier GHSR-1a agonists such as GHRP-6 produced significant increases in hunger. Ipamorelin’s selectivity profile appears to attenuate this effect: at GH-stimulating doses, appetite stimulation is modest and inconsistently reported across studies. The mechanistic basis is not fully characterised, but Ipamorelin’s pentapeptide structure may engage GHSR-1a in a conformation that preferentially recruits GH-secretory signalling over orexigenic pathways.

How important is the timing of injection relative to meals and sleep?

Timing is consequential. Elevated blood glucose and free fatty acids – both present after a meal – suppress GH secretion at the pituitary level and increase somatostatin tone. Injecting in a fasted state, or at least two hours after the last meal, removes this inhibitory background. Evening administration proximate to sleep onset aligns the exogenous pulse with the period of lowest endogenous somatostatin activity, producing the largest and most physiologically coherent response.

Should IGF-1 be monitored during use?

The literature consistently recommends it. IGF-1 is the most practical surrogate marker for cumulative GH axis activity: a single GH pulse is brief and difficult to capture, whereas IGF-1 reflects integrated secretion over days to weeks. Baseline measurement before initiation, followed by reassessment at six to eight weeks, allows dosing to be calibrated to keep IGF-1 within the upper range of age-adjusted normal rather than supraphysiological – a threshold associated with the adverse effects of GH excess.

Is there a risk of pituitary desensitisation with prolonged use?

GHRH receptor downregulation has been demonstrated in vitro and in animal models with continuous GHRH exposure. The pulsatile dosing pattern produced by CJC-1295 no DAC – and the common practice of cycling five days on, two days off, or taking periodic breaks of eight to twelve weeks – is partly motivated by this concern. Whether clinically meaningful desensitisation occurs in humans with the intermittent dosing regimens typically employed remains an open question in the literature.

Can this combination be used by women, and are there sex-specific considerations?

Women have higher baseline GH pulse frequency than men but lower pulse amplitude, and their somatotropic axis is more sensitive to oestrogen modulation. Published studies include female subjects, and no sex-specific safety signals have been identified at research doses. However, GH physiology differs meaningfully across the menstrual cycle and at menopause, and the interaction between secretagogue use and endogenous oestrogen status has not been systematically studied. These are considerations for a qualified clinician, not generalisable conclusions.

In the same family